Veklury (remdesivir)
COVID-19
Key Facts
About Ligand Pharmaceuticals
Ligand Pharmaceuticals operates a unique, asset-light business model focused on acquiring and licensing royalty rights to pharmaceutical assets and technologies, which it partners with other companies for development and commercialization. Its core achievement is building a diversified, revenue-generating portfolio from blockbuster drugs like Promacta®, Kyprolis®, and Veklury®, underpinned by its proprietary Captisol® drug formulation platform. This strategy provides predictable, high-margin royalty streams while minimizing direct exposure to clinical trial risk and commercial infrastructure costs. The company's mission is to act as a financier and enabler within the biopharma ecosystem, leveraging its scientific and financial expertise to share in the success of innovative therapies.
View full company profileOther COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |